R
Rain Therapeutics
Developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver
About Rain Therapeutics
Rain Therapeutics is a biotechnology company focused on developing targeted therapies for cancer patients. The company identifies cancers with a single, clear oncogenic driver and evaluates subpopulations of cancer patients with unmet needs where current standards of care are ineffective. Utilizing a global network of scientific and thought leaders, Rain Therapeutics matches these cancers with small molecule therapeutics designed to treat specific cancer mutations. The company's lead program, tarloxotinib, is a hypoxia-activated prodrug aimed at treating cancers with specific genetic mutations. Rain Therapeutics primarily serves patients with cancer, operating within the oncology market. The business model involves the development and commercialization of proprietary cancer therapies, generating revenue through the sale of these specialized treatments.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Fremont, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
BVF Partners
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rain Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rain Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.